Thursday, 15 October 2026European Markets

SOPRA STERIA GROUP Stock Over 21% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of sopra steria group (cac 40: sop.pa) rose by a staggering 21.69% in 10 sessions from €161.8 to €196.90 at 04:09 est on thursday, following the last session's downward trend. cac 40 is falling 0.2% to €7,324.76, after two sequential sessions in a row of losses.

sopra steria group's last close was €195.80, 10.19% above its 52-week high of €177.70.

about sopra steria group

sopra steria group sa provides consulting, digital, and software development services in france and internationally. the company operates through five segments: france, united kingdom, other europe, sopra banking software, and other solutions. it offers consulting services, including business and technology consulting services for large companies and public bodies; systems integration services that covers information system lifecycle and transformation programs; and cybersecurity services. the company also provides software for banks and financial institutions, human resources, and property management; business process services; and it infrastructure management services, as well as lending solutions. it serves customers in the retail, energy and utilities, financial services, government and public sector, transport, aerospace, defense and security, insurance, telecommunication, media and entertainment, and other industries. sopra steria group sa was incorporated in 1968 and is headquartered in paris, france.

earnings per share

as for profitability, sopra steria group has a trailing twelve months eps of €5.25.

pe ratio

sopra steria group has a trailing twelve months price to earnings ratio of 37.5. meaning, the purchaser of the share is investing €37.5 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.65%.

more news about sopra steria group (sop.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com